Key facts
- This page summarizes John K. Bell's Form 4 filing for Cure Pharmaceutical Holding Corp. (AVRW).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2021, 19:34.
John K. Bell - 20 Aug 2020 Form 4 Insider Report for Cure Pharmaceutical Holding Corp. (AVRW)
- Reporting relationship
- Director
- Issuer ticker
- AVRW
- Reported as of
- 20 Aug 2020
- Net transaction value
- $0
- Reporting owner signature
- /s/ John Bell
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
John K. Bell filed Form 4 for Cure Pharmaceutical Holding Corp. (AVRW) on 27 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVRW
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +17,601
- Change %
- Price
- $0.000000
- Shares after
- 17,601
- Date
- 20 Aug 2020
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVRW
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +61,654
- Change %
- Price
- $0.000000
- Shares after
- 61,654
- Date
- 23 Sep 2020
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,654
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a restricted stock award. This late filing is due to an inadvertent administrative error and not any error of the reporting person.
Footnote F2
The reporting person received restricted stock units under the equity incentive plan. Vesting occurs within a one-year term or until the next annual meeting of shareholders. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. This late filing is due to an inadvertent administrative error and not any error of the reporting person.